ADC Therapeutics (ADCT) CEO gets 900,000-share equity grant

Rhea-AI Filing Summary

ADC Therapeutics SA reported that Chief Executive Officer Ameet Mallik acquired 900,000 Common Shares on February 13, 2026 as part of a restricted share unit award valued at $3.99 per share. According to a footnote, these shares will be delivered over time as the RSUs vest: one-third on the first anniversary of the February 13, 2026 grant date and one-third on each of the next two anniversaries, subject to continued service.

On the same date, 103,231 Common Shares were disposed of through a tax-withholding transaction at $3.99 per share to cover Mr. Mallik’s tax obligations related to previously granted RSUs vesting. After these transactions, he directly held 1,446,769 Common Shares. A separate indirect holding of 669,101 Common Shares is reported as held by a grantor retained annuity trust, and Mr. Mallik disclaims beneficial ownership of those shares except to the extent of his pecuniary interest.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

MALLIK AMEET

(Last) (First) (Middle)

430 MOUNTAIN AVE, SUITE 404

(Street)

NEW PROVIDENCE NJ 07974

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ADC Therapeutics SA [ ADCT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/13/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	02/13/2026		A		900,000(1)	A	$3.99	1,550,000(2)	D
Common Shares	02/13/2026		F		103,231(3)	D	$3.99	1,446,769	D
Common Shares								669,101(2)	I	By grantor retained annuity trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents Common Shares to be delivered in settlement of a restricted share unit award which vests one-third on the first anniversary of the grant date, which grant date is February 13, 2026, and then one-third on each anniversary date thereafter, upon continued service through the designated vesting event.

2. Balance reflects the prior transfer of 669,101 Common Shares from the Reporting Person to a grantor retained annuity trust, which transfer is exempt from Section 16(b) pursuant to Rule 16a-13. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

3. Represents the number of Common Shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted share units previously granted.

Remarks:

	/s/ Lisa Kallebo, as Attorney-in-Fact for Ameet Mallik	02/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did ADC Therapeutics (ADCT) report for its CEO?

ADC Therapeutics reported that CEO Ameet Mallik received a grant of 900,000 Common Shares tied to restricted share units and had 103,231 shares withheld to cover tax obligations from previously vested RSUs, both dated February 13, 2026.

How will Ameet Mallik’s 900,000-share award at ADC Therapeutics vest?

The 900,000-share award vests in three equal installments. One-third vests on the first anniversary of the February 13, 2026 grant date, and one-third vests on each of the following two anniversaries, contingent on Mr. Mallik’s continued service through each vesting event.

Why were 103,231 ADC Therapeutics shares disposed of in the Form 4 filing?

The 103,231 Common Shares were withheld by ADC Therapeutics to satisfy CEO Ameet Mallik’s tax withholding obligations arising from the vesting of previously granted restricted share units, rather than being an open-market sale or discretionary disposition.

What is the reported share ownership of ADC Therapeutics’ CEO after these transactions?

After the reported transactions, CEO Ameet Mallik directly owned 1,446,769 ADC Therapeutics Common Shares. An additional 669,101 shares are held indirectly by a grantor retained annuity trust, for which he disclaims beneficial ownership except for his pecuniary interest.

What is the role of the grantor retained annuity trust in Ameet Mallik’s ADCT holdings?

A grantor retained annuity trust holds 669,101 ADC Therapeutics Common Shares associated with Ameet Mallik. The filing notes this prior transfer is exempt under Rule 16a-13 and that he disclaims beneficial ownership except to the extent of his pecuniary interest.